Generation Bio Co (NASDAQ:GBIO) shares, rose in value on Friday, June 20, with the stock price up by 5.56% to the previous day’s close as strong demand from buyers drove the stock to $0.38.
Actively observing the price movement in the last trading, the stock closed the session at $0.36. Referring to stock’s 52-week performance, its high was $3.65, and the low was $0.32. On the whole, GBIO has fluctuated by -5.45% over the past month.
With the market capitalization of Generation Bio Co currently standing at about $25.47 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-07.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that GBIO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of GBIO currently trading nearly -1.45% and -3.07% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.08, while the 7-day volatility ratio is showing 6.73% which for the 30-day chart, stands at 6.41%. Furthermore, Generation Bio Co (GBIO)’s beta value is 2.66, and its average true range (ATR) is 0.03.
A comparison of Generation Bio Co (GBIO) with its peers suggests the former has fared considerably weaker in the market. GBIO showed an intraday change of 5.56% in last session, and over the past year, it shrunk by -86.99%%.
Data on historical trading for Generation Bio Co (NASDAQ:GBIO) indicates that the trading volumes over the past 3 months, they’ve averaged 524.56K. According to company’s latest data on outstanding shares, there are 67.01 million shares outstanding.
Nearly 31.65% of Generation Bio Co’s shares belong to company insiders and institutional investors own 54.54% of the company’s shares. The stock has fallen by -64.15% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GBIO stock heading into the next quarter.
